Iftikhar and Colleagues Reply: Methodology Clarified
- 43 Downloads
We thank Gunsoy and colleagues for their comments on our paper  and appreciate the opportunity to further clarify our methods and results. The definitions of asthma exacerbations differed in different studies and was provided in each article mostly in their ‘methods’ sections. Yes, it is true, that we ‘did not extract treatment effects’ directly from the source articles. We simply used the asthma exacerbation data reported in each study (see Table for further clarification) in our meta-analysis. We never reported that some biologics increased asthma exacerbations as Gunsoy et al. imply. It is true that ‘patient-years’ were not provided in each study, which is why we specified in the methods section, that we calculated the patient-years based on the data on follow-up provided in each study. However, it is not true, that exacerbation rates were not reported ‘within most studies’ (see Table). For Chupp et al. , Bel et al. , and Castro et al.  studies, the asthma exacerbation...
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no competing interests.
- 2.Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390–400CrossRefGoogle Scholar
- 4.Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355–366CrossRefGoogle Scholar
- 7.Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781–796CrossRefGoogle Scholar